Abbott Laboratories Corporation

Richard P Poska

Sandeep Dutta

Yihong Qiu

Kevin R Engh

Howard S Cheskin

J Daniel Bollinger

A new oral polymeric controlled release formulation suitable for the once-a-day administration of valproate compounds, such as divalproex sodium, has been discovered. This formulation exhibits significant advantages over the sustained release valproate formulations of the prior art. This formulation minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This formulation follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a formulation.

Growing community of inventors

Mundelein, IL, United States of America

Richard P Poska